title: Marine lipid fraction PCSO-524 (lyprinol/omega XL) of the New Zealand green lipped mussel attenuates hyperpnea-induced bronchoconstriction in asthma.
abstract: OBJECTIVE
  Evaluate the effect of the marine lipid fraction of the New Zealand green-lipped mussel (Perna canaliculus) PCSO-524 (Lyprinol/Omega XL), rich in omega-3 fatty acids, on airway inflammation and the bronchoconstrictor response to eucapnic voluntary hyperpnea (EVH) in asthmatics.
  
  
  METHODS
  Twenty asthmatic subjects, with documented HIB, participated in a placebo controlled double-blind randomized crossover trial. Subjects entered the study on their usual diet and were then placed on 3 weeks of PCSO-524 or placebo supplementation, followed by a 2 week washout period, before crossing over to the alternative diet. Pre- and post-eucapnic voluntary hyperpnea (EVH) pulmonary function, fraction of exhaled nitric oxide (FENO), asthma symptom scores, medication use, exhaled breath condensate (EBC) pH, cysteinyl leukotrienes (cyst-LT), 8-isoprostane and urinary 9α, 11β-prostaglandin (PG)F2 and Clara (CC16) protein concentrations were assessed at the beginning of the trial and at the end of each treatment period.
  
  
  RESULTS
  The PCSO-524 diet significantly reduced (p < 0.05) the maximum fall in post-EVH FEV1 (-8.4 ± 3.2%) compared to usual (-19.3 ± 5.4%) and placebo diet (-22.5 ± 13.7%). Pre- and post- EVH EBC cyst-LT and 8-isoprostane, and urinary 9α, 11β-PGF2 and CC16 concentrations were significantly reduced (p < 0.05) on the PCSO-524 diet compared to the usual and placebo diet. EBC pH and asthma symptom scores were significantly improved (p < 0.05) and rescue medication use significantly reduced (p < 0.05) on the PCSO-524 diet compared to the usual and placebo diet.
  
  
  CONCLUSIONS
  PCSO-524 (Lyprinol)/Omega XL) may have beneficial effects in HIB and asthma by serving as a pro-resolving agonist and/or inflammatory antagonist.
authors: School of Public Health-Bloomington, Department of Kinesiology, Human Performance and Exercise Biochemistry Laboratory, 1025 E. 7th St. SPH 112, Bloomington, IN 47404, USA. tmickleb@indiana.edu
authors: Timothy D
authors: TD
authors: Mickleborough
authors: Cherissa L
authors: CL
authors: Vaughn
authors: Ren-Jay
authors: RJ
authors: Shei
authors: Eliza M
authors: EM
authors: Davis
authors: Daniel P
authors: DP
authors: Wilhite
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000178:diet therapy / Q000503:physiopathology; D001688:Biological Products / Q000008:administration & dosage*; D015415:Biomarkers / Q000032:analysis; D049872:Bivalvia; D001944:Breath Tests; D001991:Bronchitis / Q000178:diet therapy / Q000503:physiopathology; D016084:Bronchoconstriction / Q000187:drug effects; D001993:Bronchodilator Agents / Q000627:therapeutic use; D003251:Constriction, Pathologic / Q000178:diet therapy; D018592:Cross-Over Studies; D019587:Dietary Supplements; D015237:Dinoprost / Q000652:urine; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D006985:Hyperventilation / Q000503:physiopathology; D008055:Lipids / Q000008:administration & dosage*; D008297:Male; D055118:Medication Adherence; D009569:Nitric Oxide / Q000032:analysis; D014598:Uteroglobin / Q000652:urine; D055815:Young Adult
chemical_list: D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D001688:Biological Products; D015415:Biomarkers; D001993:Bronchodilator Agents; D015525:Fatty Acids, Omega-3; D008055:Lipids; C418997:lyprinol; D009569:Nitric Oxide; D014598:Uteroglobin; D015237:Dinoprost
keywords: Asthma; Diet; Inflammation; Omega-3 fatty acids